Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms

Addiction

Volumn 107, Issue 1, 2012, Pages 131-141

  Oliveto, Alison ^a   Poling, James ^b   Mancino, Michael J ^a   Williams, D Keith ^a   Thostenson, Jeff ^a   Pruzinsky, Rhonda ^b   Gonsai, Kishorchandra ^b   Sofuoglu, Mehmet ^b   Gonzalez, Gerardo ^c   Tripathi, Shanti ^a   Kosten, Thomas R ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cocaine dependence; Cognitive behavioral therapy; Placebo control; Randomized clinical trial; Relapse prevention; Sertraline

Indexed keywords

PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME; URINE;

ADOLESCENT; ADULT; AMBULATORY CARE; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 83355174255     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03552.x     Document Type: Article

References (97)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug and Alcohol Services Information System (DASIS). Primary Cocaine Treatment Admissions: 2007. Rockville, MD: Department of Health and Human Services, Office of Applied Studies; 2007.
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD: Department of Health and Human Services, Office of Applied Studies; 2007.
3. Goldstein R. A., DesLauriers C., Burda A., Johnson-Arbor K., Cocaine: History, social implications, and toxicity: A review. Seminars in Diagnostic Pathology 2009; 26(1): 10-7.
4. US Department of Health and Human Services (USDHHS). Mental Health: a report from the Surgeon General. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), 1999.
5. Perez C. M., Suarez E., Torres E. A. Epidemiology of hepatitis C infection and its public health implications in Puerto Rico. P R Health Sci J 2004; 23: 11-28.
6. Higgins S. T., Delaney D. D., Budney A. J., Bickel W. K., Hughes J. R., Foerg F. etal. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148: 1218-24.
7. Compton W. M., Cottler L. B., Abdallah A. B., Phelps D. L., Spitznagel E. L., Horton J. C. Substance dependence and other psychiatric disorders among drug dependent subjects: race and gender correlates. Amer J Addict 2000; 9: 113-25.
8. Kidorf M., Disney E. R., King V. L., Neufeld K., Beilenson P. L., Brooner R. K. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend 2004; 74: 115-22.
9. Falck R. S., Wang J., Carlson R. G., Eddy M., Siegal H. A. The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers. J Psychoact Drugs 2002; 34: 281-8.
10. Myers J. K., Weissman M. M., Tischler G. L., Holzer C. E., Leaf P. J., Orvaschel H. etal. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 1984; 41: 959-67.
11. Rounsaville B. J., Anton S. F., Carroll K., Budde D., Prusoff B. A., Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 48: 43-51.
12. Rounsaville B. J., Anton S. F., Carroll K., Budde D., Prusoff B. A., Gawin F. etal. Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study. Can J Psychiatry 2005; 50: 512-8.
13. Rounsaville B. J., Anton S. F., Carroll K., Budde D., Prusoff B. A., Gawin F. etal. Characteristics of cocaine users presenting to an emergency department chest pain observation unit. Acad Emerg Med 2005; 12: 329-37.
14. Conner K. R., Pinquart M., Holbrook A. P. Meta-analysis of depression and substance use and impairment among cocaine users. Drug Alcohol Depend 2008; 98: 13-23.
15. Kilbey M. M., Breslau N., Andreski P. Cocaine use and dependence in young adults: associated psychiatric disorders and personality traits. Drug Alcohol Depend 1992; 29: 283-90.
16. Kasarabada N. D., Anglin M. D., Khalsa-Denison E., Paredes A. Variations in psychosocial functioning associated with patterns of progression in cocaine-dependent men. Addict Behav 1998; 23: 179-89.
17. Leventhal A. M., Mooney M. E., DeLaune K. A., Schmitz J. M. Using addiction severity profiles to differentiate cocaine-dependent patients with and without comorbid major depression. Am J Addict 2006; 15: 362-9.
18. Alterman A. I., McKay J. R., Mulvaney F. D., Cnaan A., Cacciola J. S., Tourian K. A. etal. Baseline prediction of 7-month cocaine abstinence for cocaine dependence patients. Drug Alcohol Depend 2000; 59: 215-21.
19. Carroll K. M., Rounsaville B. J., Bryant K. J. Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance. J Stud Alcohol 1993; 54: 199-208.
20. McKay J. R., Pettinati H. M., Morrison R., Feeley M., Mulvaney F. D., Gallop R. Relation of depression diagnoses to 2-year outcomes in cocaine-dependent patients in a randomized continuing care study. Psychol Addict Behav 2002; 16: 225-35.
21. Schmitz J. M., Stotts A. L., Averill P. M., Rothfleisch J. M., Bailley S. E., Sayre S. L. etal. Cocaine dependence with and without comorbid depression: a comparison of patient characteristics. Drug Alcohol Depend 2000; 60: 189-98.
22. Helmus T. C., Downey K. K., Wang L. M., Rhodes G. L., Schuster C. R. The relationship between self-reported cocaine withdrawal symptoms and history of depression. Addict Behav 2001; 26: 461-7.
23. Arndt I. O., Dorozynsky L., Woody G. E., McLellan A. T., O'Brien C. P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992; 49: 888-93.
24. Batki S. L., Washburn A. M., Delucchi K., Jones R. T. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996; 41: 137-42.
25. Covi L., Hess J. M., Kreiter N. A., Haertzen C. A. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am J Drug Alcohol Abuse 1995; 21: 327-44.
26. Galloway G. P., Newmeyer J., Knapp T., Stalcup S. A., Smith D. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13: 201-16.
27. Gawin F. H., Kleber H. D., Byck R., Rounsaville B. J., Kosten T. R., Jatlow P. I. etal. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46: 117-21.
28. Grabowski J., Rhoades H., Elk R., Schmitz J., Davis C., Creson D. etal. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995; 15: 163-74.
29. Kosten T. A., Kosten T. R., Gawin F. H., Gordon L. T., Hogan L., Kleber H. D. An open trial of sertraline for cocaine abuse. Am J Addict 1992; 1: 349-53.
30. Margolin A., Kosten T. R., Avants S. K., Wilkins J., Ling W., Beckson M. etal. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125-31.
31. Nunes E. V., McGrath P. J., Quitkin F. M., Ocepek-Welikson K., Stewart J. W., Koenig T. etal. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995; 39: 185-95.
32. Weddington W. W., Jr., Brown B. S., Haertzen C. A., Hess J. M., Mahaffey J. R., Kolar A. F. etal. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991; 17: 137-52.
33. Carroll K. M., Rounsaville B. J. Psychosocial treatments for substance dependence. In: Oldham J. M., Riba M. B., editors. American Psychiatric Press Review of Psychiatry. Washington, DC: American Psychiatric Press, Inc.; 1995, p. 127-49.
34. Nunes E. V., Quitkin F. M., Donovan S. J., Deliyannides D., Ocepek-Welikson K., Koenig T. etal. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 1998; 55: 153-60.
35. Nunes E. V., Quitkin F. M., Brady R., Stewart J. W. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991; 148: 667-9.
36. Ziedonis D. M., Kosten T. R. Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol Bull 1991; 27: 337-43.
37. Schmitz J. M., Averill P., Stotts A. L., Moeller F. G., Rhoades H. M., Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001; 63: 207-14.
38. Best S. E., Malison R. T., Wallace E. A., Zoghbi S. S., Zea-Ponce Y., Baldwin R. M. etal. SPECT imaging of the dopamine transporter in cocaine abstinence: preliminary studies using [123-l]b-CIT. In: Harris L. S., editor. Problems of Drug Dependence. National Institute on Drug Abuse Research Monograph. Washington, DC: National Institute on Drug Abuse; 1994, p. 492.
39. Malison R. T., Best S. E., Wallace E. A., McCance E., Laruelle M., Zoghbi S. S. etal. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 1995; 122: 358-62.
40. Volkow N. D., Fowler J. S., Wolf A. P., Schlyer D., Shiue C. Y., Alpert R. etal. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990; 147: 719-24.
41. Parsons L. H., Smith A. D., Justice J. B. Jr. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 1991; 9: 60-5.
42. Parsons L. H., Koob G. F., Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995; 274: 1182-91.
43. Rossetti Z. L., Melis F., Carboni S., Gessa G. L. Dramatic depletion of mesolimbic extracellular dopamine after withdrawal from morphine, alcohol or cocaine: a common neurochemical substrate for drug dependence. Ann NY Acad Sci 1992; 654: 513-6.
44. Weiss F., Markou A., Lorang M. T., Koob G. F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 1992; 593: 314-8.
45. Cunningham K. A. Modulation of serotonin function by acute and chronic cocaine: neurophysiological analyses. In: Hammer R., editor. Molecular Neurobiology of Cocaine. Boca Raton, FL: CRC Press; 1995, p. 121-43.
46. Gawin F. H., Kleber H. D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986; 43: 107-13.
47. Satel S. L., Price L. H., Palumbo J. M., McDougle C. J., Krystal J. H., Gawin F. etal. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991; 148: 1712-6.
48. Weddington W. W., Brown B. S., Haertzen C. A., Cone E. J., Dax E. M., Herning R. I. etal. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. Arch Gen Psychiatry 1990; 47: 861-8.
49. Baumann M. H., Rothman R. B. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol Psychiatry 1998; 44: 578-91.
50. Jimerson D. C. Role of dopamine mechanisms in the affective disorders. In: Meltzer H. Y., editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987, p. 505-11.
51. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994; 115: 454-62.
52. Benloucif S., Keegan M. J., Galloway M. P. Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 1993; 265: 373-7.
53. Parsons L. H., Justice J. B. Jr. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 1993; 606: 195-9.
54. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993; 16: 387-400.
55. Cowen P. J. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 1993; 16: S6-18.
56. Meltzer H. Y., Lowry M. T. The serotonin hypothesis of depression. In: Meltzer H. Y., editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987, p. 513-26.
57. Koe B. K., Weissman A., Welch W. M., Browne R. G. Sertraline, 1S, 4S-N-methyl-4-(3, 4-dichlorophenyl)-1, 2, 3, 4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 226: 686-700.
58. Goodnick P. J., Goldstein B. J. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J Psychopharmacol 1998; 12: S5-20.
59. Tatsumi M., Jansen K., Blakely R. D., Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368: 277-83.
60. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9.
61. Guthrie S. K. Sertraline: a new specific serotonin reuptake blocker. Drug Intell Clin Pharm 1991; 25: 952-61.
62. Richelson E. Pharmacology of antidepressants-characteristics of the ideal drug. Mayo Clin Proc 1994; 69: 1069-81.
63. Stahl S. M. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 1998; 59: 343-4.
64. Jans L. A. W., Riedel W. J., Markus C. R., Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007; 12: 522-43.
65. Carver C. S., Johnson S. L., Joorman J. Serotonergic function: two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression. Psychol Bull 2008; 134: 912-43.
66. Filip M., Frankowska M., Zaniewska M., Golda A., Przegalinski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 2005; 57: 685-700.
67. Filip M., Alenina N., Bader M., Przegalinski E. Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction. Addict Biol 2010; 15: 227-49.
68. Wei L. J., Lachin J. M. Properties of the urn randomization in clinical trials. Control Clin Trials 1988; 9: 345-64.
69. Carroll K. M. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. Rockville, MD: National Institute on Drug Abuse; 1998, p. 98-4308.
70. Preskorn S. H., Lane R. M. Sertraline 50mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 129-41.
71. First M. B., Spitzer R. L., Gibbon M., Williams J. B. W. Structured Clinical Interview for DSM-IV, Patient edition. Washington, DC: American Psychiatric Press; 1995.
72. McLellan A. T., Luborsky L., Woody G. E., O'Brien C. P. An improved diagnostic instrument for substance abuse subjects: the addiction severity index. J Nerv Ment Dis 1980; 168: 26-33.
73. Kampman K. M., Volpicelli J. R., McGinnis D. E., Alterman A. I., Weinrieb R. M., D'Angelo L. etal. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998; 23: 449-61.
74. Mulvaney F. D., Alterman A. I., Boardman C. R., Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat 1999; 16: 129-35.
75. Hamilton M. A. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-82.
76. Kosten T., Oliveto A., Feingold A., Poling J., Sevarino K., McCance-Katz E. etal. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70: 315-25.
77. Oliveto A., Poling J., Sevarino K. A., Gonsai K. R., McCance-Katz E. F., Stine S. M. etal. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend 2005; 79: 157-65.
78. Moeller F. G., Schmitz J. M., Steinberg J. L., Green C. M., Reist C., Lai L. Y. etal. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33: 367-78.
79. Piasecki M. P., Steinagel G. M., Thienhaus O. J., Kohlenberg B. S. An exploratory study: the use of paroxetine for methamphetamine craving. J Psychoact Drugs 2002; 34: 301-4.
80. Winhusen T. M., Somoza E. C., Harrer J. M., Mezinskis J. P., Montgomery M. A., Goldsmith R. J. etal. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005; 100: 68-77.
81. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Jeff D. etal. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12-8.
82. Batki S. L., Manfredi L. B., Jacob P., III, Jones R. T. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol 1993; 13: 243-50.
83. Pollack M. H., Rosenbaum J. F. Fluoxetine treatment of cocaine abuse in heroin addicts. J Clin Psychiatry 1991; 52: 31-3.
84. Schmitz J. M., Rhoades H. M., Elk R., Creson D., Hussein I., Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998; 6: 162-8.
85. Cornelius J. R., Salloum I. M., Thase M. E., Haskett R. F., Daley D. C., Jones-Barlock A. etal. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998; 34: 117-21.
86. Petrakis I. etal. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998; 50: 221-6.
87. Carrasco J. L., Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005; 59: 1428-34.
88. Palvimaki E. P., Kuoppamaki M., Syvalahti E., Hietala J. Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain. Int J Neuropsychopharmacol 1999; 2: 95-9.
89. Buchman N., Strous R. D., Baruch Y. Side effects of long-term treatment with fluoxetine. Clin Neuropharmacol 2002; 25: 55-7.
90. Thase M. E. Treatment issues related to sleep and depression. J Clin Psychiatry 2000; 61: 46-50.
91. Brymer C., Winograd C. H. Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 1992; 40: 902-5.
92. Millan M. J., Dekeyne A., Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998; 37: 953-5.
93. Owens M. J., Knight D. L., Nemeroff C. B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-50.
94. Rothman R. B., Blough B. E., Baumann M. H. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol 2008; 16: 458-74.
95. Husband S. D., Marlowe D. B., Lamb R. J., Iguchi M. Y., Bux D. A., Kirby K. C. etal. Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts. J Consult Clin Psychol 1996; 64: 221-4.
96. Kadden R. M., Kranzler H. R., Rounsaville B. J. Validity of the distinction between 'substance-induced' and 'independent' depression and anxiety disorders. Am J Addiction 1995; 4: 107-17.
97. Mancino M. J., Feldman Z., Chopra M. P., Cargile C., Oliveto A. A randomized placebo-controlled trial of sertraline and sertraline plus gabapentin in depressed, recently abstinent cocaine-dependent patients. 2009 Annual Meeting of the College on Problems of Drug Dependence. Reno/Sparks, NV. 2009.